1. AMEDEO HIV Infection
2010-11-29
________________ ** New articles ** _________________
1. MCGRATH CJ, Chung MH, Richardson BA, Benki-Nugent S, et al.
Younger age at HAART initiation is associated with more rapid growth reconstitution.
AIDS. 2010.
ABSTRACT available
2. LI JC, Au KY, Fang JW, Yim HC, et al.
HIV-1 trans-activator protein dysregulates IFN-gamma signaling and contributes to the suppression of autophagy induction.
AIDS. 2010.
ABSTRACT available
3. SANCHEZ J, Sal Y Rosas VG, Hughes JP, Baeten JM, et al.
Male circumcision and risk of HIV acquisition among men who have sex with men.
AIDS. 2010.
ABSTRACT available
4. KANDALA NB, Brodish P, Buckner B, Foster S, et al.
Millennium development goal 6 and HIV infection in Zambia: what can we learn from
successive household surveys?
AIDS. 2010.
ABSTRACT available
5. LORENTE E, Infantes S, Barnea E, Beer I, et al.
TAP-independent human histocompatibility complex-Cw1 antigen processing of an HIV
envelope protein conserved peptide.
AIDS. 2010.
ABSTRACT available
6. PATHANAPITOON K, Riemens A, Kongyai N, Sirirungsi W, et al.
Intraocular and plasma HIV-1 RNA loads and HIV uveitis.
AIDS. 2010.
ABSTRACT available
7. HOWE CJ, Cole SR, Ostrow DG, Mehta SH, et al.
A prospective study of alcohol consumption and HIV acquisition among injection
drug users.
AIDS. 2010.
ABSTRACT available
8. HARRIGAN PR, Geretti AM.
Genotypic tropism testing: evidence-based or leap of faith?
AIDS. 2010.
9. WATERS L, Fisher M, Winston A, Higgs C, et al.
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot
study to assess the feasibility of switching individuals receiving efavirenz with
continuing central nervous system adverse events to etravirine.
AIDS. 2010.
ABSTRACT available
10. RALLON NI, Restrepo C, Naggie S, Lopez M, et al.
Interleukin-28B gene polymorphisms do not influence the susceptibility to
HIV-infection or CD4 cell decline.
AIDS. 2010.
ABSTRACT available
11. SALGADO M, Kirk GD, Cox A, Rutebemberwa A, et al.
Protective interleukin-28B genotype affects hepatitis C virus clearance, but does
not contribute to HIV-1 control in a cohort of African-American elite
controllers/suppressors.
AIDS. 2010.
ABSTRACT available
12. GETAHUN H, Granich R, Sculier D, Gunneberg C, et al.
Implementation of isoniazid preventive therapy for people living with HIV
worldwide: barriers and solutions.
AIDS. 2010;24 Suppl 5:S57-65.
13. CHARALAMBOUS S, Grant AD, Innes C, Hoffmann CJ, et al.
Association of isoniazid preventive therapy with lower early mortality in
individuals on antiretroviral therapy in a workplace programme.
AIDS. 2010;24 Suppl 5:S5-13.
ABSTRACT available
14. DUROVNI B, Cavalcante SC, Saraceni V, Vellozo V, et al.
The implementation of isoniazid preventive therapy in HIV clinics: the experience
from the TB/HIV in Rio (THRio) study.
AIDS. 2010;24 Suppl 5:S49-56.
ABSTRACT available
15. LESTER R, Hamilton R, Charalambous S, Dwadwa T, et al.
Barriers to implementation of isoniazid preventive therapy in HIV clinics: a
qualitative study.
AIDS. 2010;24 Suppl 5:S45-8.
ABSTRACT available
16. GRANT AD, Mngadi KT, van Halsema CL, Luttig MM, et al.
Adverse events with isoniazid preventive therapy: experience from a large trial.
AIDS. 2010;24 Suppl 5:S29-36.
ABSTRACT available
17. CHURCHYARD GJ, Fielding KL, Lewis JJ, Chihota VN, et al.
Symptom and chest radiographic screening for infectious tuberculosis prior to
starting isoniazid preventive therapy: yield and proportion missed at screening.
AIDS. 2010;24 Suppl 5:S19-27.
ABSTRACT available
18. GRANT AD, Fielding KL, Charalambous S, Chaisson RE, et al.
Why have trials of isoniazid preventive therapy among people with HIV infection
not demonstrated an effect on mortality?: did close examination of the trees
obscure our view of the wood?
AIDS. 2010;24 Suppl 5:S15-8.
19. ELDRED LJ, Churchyard G, Durovni B, Godfrey-Faussett P, et al.
Isoniazid preventive therapy for HIV-infected people: evidence to support
implementation.
AIDS. 2010;24 Suppl 5:S1-3.
20. SPIVAK A, Rabi A, McMahon MA, Shan L, et al.
Dynamic Constraints on the Second Phase Compartment of HIV-infected Cells.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
21. ALMEIDA J, Letang E, Nhampossa T, Ayala E, et al.
Rapid suppression of HIV-RNA is associated with improved control of immune
activation in a Mozambican adults initiating antiretroviral therapy with low CD4
counts.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
22. PRICE MA, Wallis CL, Lakhi S, Karita E, et al.
Transmitted HIV Type 1 Drug Resistance Among Individuals with Recent HIV
Infection in East and Southern Africa.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
23. FONTAINE J, Poudrier J, Roger M.
Persistence of high blood levels of the chemokines CCL2, CCL19 and CCL20 during
the course of HIV infection.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
24. MESTECKY J, Wright PF, Lopalco L, Staats HF, et al.
Scarcity or Absence of Humoral Immune Responses in the Plasma and Cervicovaginal
Lavage Fluids of Heavily HIV-1-Exposed But Persistently Seronegative Women.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
25. EL ANNAZ H, Recordon-Pinson P, Baba N, Sedrati O, et al.
Presence of drug resistance mutations among drug-naive patients in Morocco.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
26. MONTEIRO JP, Araujo AF, Santos ED, Galvao-Castro B, et al.
LACK OF HIGH-LEVEL RESISTANCE MUTATIONS IN HIV-1 BF RECOMBINANT STRAINS
CIRCULATING IN NORTHEAST BRAZIL.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
27. TRUONG HH, Fritz K, McFarland W, Hartogensis W, et al.
Recent HIV-1 Infection Among Participants in a Same-Day Mobile Testing Pilot
Study in Zimbabwe.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
28. FRANCA RF, Castro-Jorge LA, Jorge DM, Neto RP, et al.
Genotypic characteristics of HIV-1 based on gp120 hypervariable region 3 of
isolates from southern Brazil.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
29. IWERIEBOR B, Bessong PO, Mavhandu GL, Masebe TM, et al.
Genetic analysis of the near full-length genome of an HIV type1 A1/C unique
recombinant from northern South Africa.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
30. NATUKUNDA E, Musiime V, Ssali F, Kizito H, et al.
A Case of Cryptococcal Lymphadenitis in an HIV-Infected Child.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
31. VAN DER KUYL AC, Jurriaans S, Back NK, Sprenger HG, et al.
Unusual Cluster of HIV Type 1 Dual Infections in Groningen, the Netherlands.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
32. YANG OO, Daar ES, Ng HL, Shih R, et al.
Increasing CTL Targeting of Conserved Sequences During Early HIV-1 Infection Is
Correlated to Decreasing Viremia.
AIDS Res Hum Retroviruses. 2010.
ABSTRACT available
33. JEENA PM, Bishai WR, Pasipanodya JG, Gumbo T, et al.
In silico Children and the Glass Mouse: Clinical Trial Simulations to Identify
and Individualize Optimal Isoniazid Doses in Children With Tuberculosis.
Antimicrob Agents Chemother. 2010.
ABSTRACT available
34. MOHAMEDBHAI SG, Sibson K, Marafioti T, Kayani I, et al.
Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases
of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%
Br J Haematol. 2010 Nov 24. doi: 10.1111/j.1365-2141.2010.08447.
ABSTRACT available
35. MUELLER SM, Spriewald BM, Bergmann S, Eismann K, et al.
Influence of Major HIV-1 Protease Inhibitor Resistance Mutations on CTL
Recognition.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
36. LE CLERC S, Coulonges C, Delaneau O, Van Manen D, et al.
Screening Low Frequency SNPS From Genome Wide Association Study Reveals A New
Risk Allele for Progression to Aids.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
37. LIU FL, Qiu YQ, Li H, Kuang YQ, et al.
An HIV-1 Resistance Polymorphism in TRIM5alpha Gene among Chinese Intravenous
Drug Users.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
38. KLAUSNER JD, Serenata C, O'bra H, Mattson CL, et al.
Scale-up and Continuation of Antiretroviral Therapy in South African Treatment
Programs, 2005-2009.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
39. LOUTFY MR, Genebat M, Moore D, Raboud J, et al.
A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of
combination antiretroviral therapy is associated with increased mortality in
HIV-infected individuals with viral suppression.
J Acquir Immune Defic Syndr. 2010;55:451-9.
ABSTRACT available
40. KYEYUNE R, den Boon S, Cattamanchi A, Davis JL, et al.
Causes of early mortality in HIV-infected TB suspects in an East African referral
hospital.
J Acquir Immune Defic Syndr. 2010;55:446-50.
ABSTRACT available
41. RUEL TD, Kamya MR, Li P, Pasutti W, et al.
Early Virologic Failure and the Development of Antiretroviral Drug Resistance
Mutations in HIV-Infected Ugandan Children.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
42. NAMUKWAYA Z, Mudiope P, Kekitiinwa A, Musoke P, et al.
The Impact of Maternal Highly Active Antiretroviral Therapy and Short-Course
Combination Antiretrovirals for Prevention of Mother-to-Child Transmission on
Early Infant Infection Rates at the Mulago National Referral Hospital in Kampala,
Uganda, January 2007 to May 2009.
J Acquir Immune Defic Syndr. 2010.
ABSTRACT available
43. BALLANA E, Pauls E, Clotet B, Perron-Sierra F, et al.
{beta}5 Integrin Is the Major Contributor to the {alpha}v Integrin-Mediated
Blockade of HIV-1 Replication.
J Immunol. 2010.
ABSTRACT available
44. SILVA RJ, Casseb J, Andreoli MA, Villa LL, et al.
Persistence and clearance of HPV from the penis of men infected and non-infected
with HIV.
J Med Virol. 2011;83:127-31.
ABSTRACT available
45. BHANICH SUPAPOL W, Remis RS, Raboud J, Millson M, et al.
Prevalence and correlates of GB virus C infection in HIV-infected and
HIV-uninfected pregnant women in Bangkok, Thailand.
J Med Virol. 2011;83:33-44.
ABSTRACT available
46. KATZ BZ, Salimi B, Gadd SL, Huang CC, et al.
Differential gene expression of soluble CD8+ T-cell mediated suppression of HIV
replication in three older children.
J Med Virol. 2011;83:24-32.
ABSTRACT available
47. WANG D, Kang XJ, Li LB, Xie QD, et al.
In vitro study on vertical transmission of the HIV-1 gag gene by human sperm.
J Med Virol. 2011;83:16-23.
ABSTRACT available
48. STEERS NJ, Currier JR, Kijak GH, di Targiani RC, et al.
Cell Type-Specific Proteasomal Processing of HIV-1 Gag-p24 Results in an Altered
Epitope Repertoire.
J Virol. 2010.
ABSTRACT available
49. LORENZO-REDONDO R, Borderia AV, Lopez-Galindez C.
Dynamics of HIV-1 "in vitro" fitness recovery.
J Virol. 2010.
ABSTRACT available
50. CRAWFORD H, Matthews PC, Schaefer M, Carlson JM, et al.
The hypervariable HIV-1 capsid protein residues comprise HLA-driven CD8+ T-cell
escape mutations and covarying HLA-independent polymorphisms.
J Virol. 2010.
ABSTRACT available
51. DENNISON SM, Anasti K, Scearce RM, Sutherland L, et al.
Non-neutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show
polyreactivity for binding to phospholipids and protein autoantigens.
J Virol. 2010.
ABSTRACT available
52. KELLER PW, Adamson CS, Heymann JB, Freed EO, et al.
The HIV-1 Maturation Inhibitor Bevirimat Stabilizes the Immature Gag Lattice.
J Virol. 2010.
ABSTRACT available
53. XING L, Liang C, Kleiman L.
Coordinate roles of Gag and RNA helicase A in promoting the annealing of tRNALys3
to HIV-1 RNA.
J Virol. 2010.
ABSTRACT available
54. MAJERCIAK V, Uranishi H, Kruhlak M, Pilkington GR, et al.
Kaposi sarcoma-associated herpesvirus ORF57 interacts with cellular RNA export
cofactors RBM15 and OTT3 promoting viral ORF59 expression.
J Virol. 2010.
ABSTRACT available
55. MICHAEL NL.
Oral Preexposure Prophylaxis for HIV - Another Arrow in the Quiver?
N Engl J Med. 2010.
ABSTRACT available
56. GRANT RM, Lama JR, Anderson PL, McMahan V, et al.
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.
N Engl J Med. 2010.
ABSTRACT available
57. QVIST T, Engsig F, Kronborg G, Larsen CS, et al.
Predictors of unsafe sex among HIV patients in Denmark: A population-based cohort
study.
Scand J Infect Dis. 2010.
ABSTRACT available
58. DOLTER KE, Evans CF, Ellefsen B, Song J, et al.
Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic
DNA vaccine for HIV-1, delivered by in vivo electroporation.
Vaccine. 2010.
ABSTRACT available
59. ZAROCOSTAS J.
New HIV infections fall by a sixth in a decade.
BMJ. 2010;341:c6739.
60. ROEHR B.
HIV drugs halve infection rate in men who have sex with men, study finds.
BMJ. 2010;341:c6737.
61. ROEHR B.
Pope's comment on condom use will help HIV prevention, say activists.
BMJ. 2010;341:c6734.
62. BENDAVID E, Leroux E, Bhattacharya J, Smith N, et al.
The relation of price of antiretroviral drugs and foreign assistance with
coverage of HIV treatment in Africa: retrospective study.
BMJ. 2010;341:c6218.
ABSTRACT available
63. HUNTINGTON S, Chadborn T, Rice B, Brown A, et al.
Travel for HIV care in England: a choice or a necessity?
HIV Med. 2010 Nov 22. doi: 10.1111/j.1468-1293.2010.00891.
ABSTRACT available
_____________________ ** End ** ______________________
We have screened the following journals for you:
AIDS
AIDS Clin Care
AIDS Read
AIDS Res Hum Retroviruses
Am J Epidemiol
Am J Hematol
Am J Med
Ann Intern Med
Ann Neurol
Antimicrob Agents Chemother
Antivir Ther
Arch Dermatol
Arch Dis Child
Arch Intern Med
Arch Neurol
Blood
BMJ
Br J Dermatol
Br J Haematol
Cancer
Cell
Clin Infect Dis
Dermatology
Drugs
HIV Med
Immunology
Int J Cancer
Int J Dermatol
J Acquir Immune Defic Syndr
J Am Acad Dermatol
J Clin Immunol
J Clin Invest
J Clin Oncol
J Immunol
J Infect Dis
J Med Virol
J Pediatr
J Virol
JAMA
Lancet
MMWR
N Engl J Med
Nat Med
Nature
Neurology
Pediatr Infect Dis J
Pediatrics
Proc Natl Acad Sci U S A
Scand J Infect Dis
Science
Vaccine
Virology
_________________________________________________________
